Relapse Rate and Time to First Relapse were Improved with Ublituximab vs Teriflunomide in the Phase 3 ULTIMATE I and ULTIMATE II Studies in Patients with Relapsing Multiple Sclerosis (RMS)

Drug Category: Array
Conference Category: Array
Lead Author: Steinman L, et al.
Published Date: 05/04/2022
Download Link: /wp-content/uploads/2022/04/Steinman_Oral_Time-to-First-Relapse_AAN_2022.pdf
Download Text: Download
Popup Confirmation?:
site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
astra-migrate-meta-layouts: set
Scroll to Top